877068-88-7

Basic information

• Product Name: (2S,4R)-1-((S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid methyl ester
• Synonyms: (2S,4R)-1-((S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid methyl ester
• CAS NO: 877068-88-7
• Molecular Weight: 603.715
• Mol File: 877068-88-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2S,4R)-1-((S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-1-((S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid methyl ester(877068-88-7)
• EPA Substance Registry System: (2S,4R)-1-((S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid methyl ester(877068-88-7)

Safety Data

• Hazardous Substances Data: 877068-88-7(Hazardous Substances Data)

Upstream product

• 50715-28-1 cyclopentyl chloroformate 
• 572924-00-6 N-[(cyclopentyloxy)carbonyl]-L-tert-leucine 
• 737750-26-4 (2S,4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid methyl ester 
• 445306-09-2 (2S,4R)-1-((S)-2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid methyl ester 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 20430-72-2 7-methoxy-2-phenylquinolin-4-ol 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 259214-70-5 (2S,4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 

Relevant articles and documents

ANTIVIRAL PHOSPHINATE COMPOUNDS

The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: Discovery of potent and specific tripeptide inhibitors

The inadequate efficacy and tolerability of current therapies for the infectious liver disease caused by the hepatitis C virus have warranted significant efforts in the development of new therapeutics. We have previously reported competitive peptide inhib